Market Place
Sourcing Support
ORYZON Reports Q3 2024 Financial Results And Update
24 Oct 2024 //
GLOBENEWSWIRE
ORYZON Receives FDA Minutes on PORTICO-2 vafidemstat Trial
01 Oct 2024 //
GLOBENEWSWIRE
Oryzon Presents Final PORTICO Vafidemstat BPD Trial Data
23 Sep 2024 //
GLOBENEWSWIRE
ORYZON Receives Patent Intent For Vafidemstat In Borderline Personality
11 Sep 2024 //
GLOBENEWSWIRE
ORYZON Announces First Patient Dosed In Phase Ib Study
09 Sep 2024 //
GLOBENEWSWIRE
ORYZON Strengthens Patent Portfolio for Vafidemstat with New Grant
03 Sep 2024 //
GLOBENEWSWIRE
ORYZON to Provide Corporate Progress Updates at Several Events in September
29 Aug 2024 //
GLOBENEWSWIRE
ORYZON Reports H1 2024 Financial Results And Corporate Update
31 Jul 2024 //
GLOBENEWSWIRE
ORYZON To Receive Two Important Patents For Vafidemstat In Japan
08 Jul 2024 //
GLOBENEWSWIRE
ORYZON Announces Voting Results From 2024 Annual General Meeting Of Shareholders
28 Jun 2024 //
GLOBENEWSWIRE
ORYZON Present of Final Data From Vafidemstat’s Global Phase IIb Trial
26 Jun 2024 //
GLOBENEWSWIRE
ORYZON`s Iadademstat ALICE Phase 2a Results Published In Lancet Hematology
03 Jun 2024 //
GLOBENEWSWIRE
ORYZON to Provide Corporate Progress Updates at Several Events in June
30 May 2024 //
GLOBENEWSWIRE
ORYZON In EU IPCEI Health Sector Med4Cure Project
29 May 2024 //
GLOBENEWSWIRE
ORYZON to Provide Corporate Progress Updates at Several Events in May
09 May 2024 //
GLOBENEWSWIRE
ORYZON Reports Q1 2024 Financials, Corporate Update
06 May 2024 //
GLOBENEWSWIRE
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
22 Apr 2024 //
GLOBENEWSWIRE
ORYZON Announces FDA Clearance of Iadademstat for SCLC
08 Apr 2024 //
GLOBENEWSWIRE
ORYZON to Provide Corporate Progress Updates at Several Events in April
05 Apr 2024 //
GLOBENEWSWIRE
ORYZON Reports Financial Results for Quarter Ended December 31, 2023
26 Feb 2024 //
GLOBENEWSWIRE
ORYZON to Provide Corporate Progress Updates at Several Events in February-March
05 Feb 2024 //
GLOBENEWSWIRE
ORYZON to Host KOL Event on PIIb PORTICO Topline Study Results of Vafidemstat
19 Jan 2024 //
GLOBENEWSWIRE
Oryzon med fails to improve borderline personality disorder
07 Jan 2024 //
FIERCE BIOTECH
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat
05 Jan 2024 //
GLOBENEWSWIRE
ORYZON to Provide Corporate Progress Updates at Several Events in January
03 Jan 2024 //
GLOBENEWSWIRE
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.
04 Dec 2023 //
GLOBENEWSWIRE
ORYZON Announces a New Financing Through a Convertible Bond Program
21 Nov 2023 //
GLOBENEWSWIRE
ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for BPD
07 Nov 2023 //
GLOBENEWSWIRE
ORYZON to Provide Corporate Progress Updates at Several Events in November
06 Nov 2023 //
GLOBENEWSWIRE
ORYZON Reports Financial Results for Quarter Ended September 30, 2023
27 Oct 2023 //
GLOBENEWSWIRE
ORYZON presents safety data from vafidemstat™s ongoing Phase IIb trial
10 Oct 2023 //
GLOBENEWSWIRE
ORYZON Receives Two Grants to Further Explore the Role of Epigenetic Targets
03 Oct 2023 //
GLOBENEWSWIRE
ORYZON to Provide Corporate Progress Updates at Several Events in October
02 Oct 2023 //
GLOBENEWSWIRE
ORYZON to Give Updates on Corporate Progress in September
05 Sep 2023 //
GLOBENEWSWIRE
Oryzon Announces Completed Patient Recruitment in Ph IIb Trial of vafidemstat
26 Jul 2023 //
GLOBENEWSWIRE
ORYZON Reports Financial Results for Half-Year Ending June 30, 2023
24 Jul 2023 //
GLOBENEWSWIRE
Positive Aggregate Safety Data From Vafidemstat`s PIIb Trial in BPD
05 Jul 2023 //
GLOBENEWSWIRE
Positive Preclinical Data of ORY-4001 for Treatment of Charcot-Marie-Tooth (CMT)
21 Jun 2023 //
GLOBENEWSWIRE
ORYZON to Present Positive Preclinical Efficacy Data of ORY-4001
30 May 2023 //
GLOBENEWSWIRE
ORYZON to Present Trial in Progress Phase Ib FRIDA Study at ASCO
17 May 2023 //
GLOBENEWSWIRE
ORYZON ReportsFYR &Corporate Update for Quarter Ended March 31, 2023
10 May 2023 //
GLOBENEWSWIRE
ORYZON to Give Updates on Corporate Progress in May-June
09 May 2023 //
GLOBENEWSWIRE
ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO
03 Apr 2023 //
GLOBENEWSWIRE
ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat
15 Mar 2023 //
GLOBENEWSWIRE
ORYZON Announces Clinical Candidate Nomination of ORY-4001
13 Mar 2023 //
GLOBENEWSWIRE
ORYZON Hosting Webinar on Targeting Lysine Specific Demethylase 1
22 Feb 2023 //
GLOBENEWSWIRE
ORYZON Reports Financial Results for Quarter Ended December 31, 2022
17 Feb 2023 //
GLOBENEWSWIRE
ORYZON to Give Updates on Corporate Progress in February-March
06 Feb 2023 //
GLOBENEWSWIRE
ORYZON Announces First Patient in NET, a PII Basket Study With Iadademstat
18 Jan 2023 //
GLOBENEWSWIRE
ORYZON to Give Updates on Corporate Progress in January
05 Jan 2023 //
GLOBENEWSWIRE
ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat
16 Dec 2022 //
GLOBENEWSWIRE
ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients
12 Dec 2022 //
GLOBENEWSWIRE
ORYZON Announces FDA Clearance of IND to Initiate Collaborative Phase II Study
09 Nov 2022 //
GLOBENEWSWIRE
ORYZON Announces Oral Data Presentation at the Upcoming 64th American Society
07 Nov 2022 //
GLOBENEWSWIRE
ORYZON to Give Updates on Corporate Progress in October
03 Oct 2022 //
GLOBENEWSWIRE
ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s
16 Sep 2022 //
GLOBENEWSWIRE
ORYZON Collaborates with the CMT Research Foundation in the US
26 Jul 2022 //
GLOBENEWSWIRE
ORYZON Enters CRADA with U.S. NCI to Develop Iadademstat in Different Cancers
19 Jul 2022 //
GLOBENEWSWIRE
Spain`s Oryzon shares soar after US Cancer Institute agrees to test new drug
19 Jul 2022 //
REUTERS
ORYZON Announces a New Financing Through a Convertible Bond Program
05 Jul 2022 //
GLOBENEWSWIRE
